Bacteremias and invasive fungal diseases in children receiving etanercept for steroid-resistant acute GVHD

Bone Marrow Transplantation

Volumn 46, Issue 1, 2011, Pages 159-160

  Faraci, M ^a   Lanino, E ^a   Morreale, G ^a   Giardino, S ^a   Fossati, M ^a   Moroni, C ^a   Caviglia, I ^a   Castagnola, E ^a  

^a G GASLINI INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; COTRIMOXAZOLE; ETANERCEPT; FLUCONAZOLE; IMTIX; MEPREDNISONE; STEROID; THYMOCYTE ANTIBODY; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG;

ABSIDIA; ACUTE GRAFT VERSUS HOST DISEASE; ALLOGENEIC STEM CELL TRANSPLANTATION; ASPERGILLUS NIGER; BACTEREMIA; BACTERIUM DETECTION; CANDIDA PARAPSILOSIS; CHILD; CLINICAL ARTICLE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; FUNGAL DETECTION; GRAFT VERSUS HOST REACTION; HERPES SIMPLEX; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RATE; LETTER; LOW DRUG DOSE; MYCOSIS; PNEUMOCYSTIS JIROVECI; PREVALENCE; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT RESPONSE;

ADOLESCENT; BACTEREMIA; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DRUG RESISTANCE; GRAFT VS HOST DISEASE; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; ITALY; MYCOSES; RECEPTORS, TUMOR NECROSIS FACTOR; STEM CELL TRANSPLANTATION;

EID: 78651371158     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2010.80     Document Type: Letter

References (9)

1. Levine JE, Paczesny S, Mineishi S, Braun T, Choi SW, Hutchinson RJ et al. Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host disease. Blood 2008; 111: 2470-2475.
2. Alousi AM, Weisdorf DJ, Logan BR, Bolanos-Meade J, Carter S, Difronzo N et al. Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: A randomized phase 2 trial from the blood and marrow transplant clinical trials network. Blood 2009; 114: 511-517.
3. Ferrara JL. Advances in the clinical management of GVHD. Best Pract Res Clin Haematol 2008; 21: 677-682.
4. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: Systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006; 295: 2275-2285.
5. Tsiodras S, Samonis G, Boumpas DT, Kontoyiannis DP. Fungal infections complicating tumor necrosis factor alpha blockade therapy. Mayo Clin Proc 2008; 83: 181-194.
6. Busca A, Locatelli F, Marmont F, Ceretto C, Falda M. Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft-versushost disease following allogeneic hematopoietic stem cell transplantation. Am J Hematol 2007; 82: 45-52.
7. Weisdorf D, Haake R, Blazar B, Miller W, McGlave P, Ramsay N et al. Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: An analysis of clinical risk features and outcome. Blood 1990; 75: 1024-1030.
8. De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46: 1813-1821.
9. Castagnola E, Bagnasco F, Faraci M, Caviglia I, Caruso S, Cappelli B et al. Incidence of bacteremias and invasive mycoses in children undergoing allogeneic hematopoietic stem cell transplantation: A single center experience. Bone Marrow Transplant 2008; 41: 339-347.